Serum proteomic profiling reveals that the fatty acid synthase (fasn) inhibitor denifanstat provides metabolic benefits via increasing fibroblast growth factor 19 (fgf-19) and decreasing 3-hydroxy-3-methylglutaryl-coa synthase 1 (hmgcs1) in nash patients